Cassava Sciences, Inc. (SAVA)
NASDAQ: SAVA · Real-Time Price · USD
1.580
-0.080 (-4.82%)
Apr 25, 2025, 12:30 PM EDT - Market open
Cassava Sciences Employees
Cassava Sciences had 30 employees as of December 31, 2024. The number of employees increased by 1 or 3.45% compared to the previous year.
Employees
30
Change (1Y)
1
Growth (1Y)
3.45%
Revenue / Employee
n/a
Profits / Employee
-$811,400
Market Cap
76.33M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SAVA News
- 3 days ago - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development - GlobeNewsWire
- 4 weeks ago - Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug - Reuters
- 4 weeks ago - Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop - Benzinga
- 4 weeks ago - Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data - GlobeNewsWire
- 7 weeks ago - Cassava Sciences Reports 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm - PRNewsWire
- 2 months ago - SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
- 2 months ago - Shareholders of Cassava Sciences, Inc. Should Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA - PRNewsWire